Skip to main content
. 2019 Jun 20;62(9):1616–1627. doi: 10.1007/s00125-019-4915-0

Fig. 2.

Fig. 2

Expected cumulative incidence of rapid progression if a clinical trial was enriched with the top percentile of possible participants according to their risk score in SDRNT1BIO (a) and FinnDiane (b). The baseline model contained only age, sex, diabetes duration, study day eGFR and length of follow-up (red line) or a model augmented with CD27 and KIM-1 (blue line). The observed event rate is represented by the horizontal dashed line